Powder: -20°C for 3 years | In solvent: -80°C for 1 year
HPN-01 is a selective IKK inhibitor (pIC50s: 6.4, 7.0, and <4.8 for IKK-α, IKK-β, and IKK-ε). HPN-01 displays greater 50-fold selectivity over a panel of more than 50 other kinases, including ALK5, CDK-2, ErbB2, EGFR, GSK3β, Src, PLK1, and VEGFR-2.
规格 | 价格/CNY | 货期 | 数量 | |
---|---|---|---|---|
2 mg | ¥ 1,540 | 5日内发货 | ||
5 mg | ¥ 2,610 | 5日内发货 | ||
25 mg | ¥ 9,160 | 6-8周 | ||
50 mg | ¥ 11,900 | 6-8周 | ||
100 mg | ¥ 17,500 | 6-8周 |
产品描述 | HPN-01 is a selective IKK inhibitor (pIC50s: 6.4, 7.0, and <4.8 for IKK-α, IKK-β, and IKK-ε). HPN-01 displays greater 50-fold selectivity over a panel of more than 50 other kinases, including ALK5, CDK-2, ErbB2, EGFR, GSK3β, Src, PLK1, and VEGFR-2. |
靶点活性 | IKKε:4.8(pIC50), IKKα:6.4(pIC50), IKKβ:7(pIC50) |
体外活性 | HPN-01 inhibits the expression of SREBP-1and SREBP-2 in cultured primary human hepatocytes with IC50s of 1.71 μΜ and 3.43 μΜ, respectively. HPN-01 is being development for the treatment of nonalcoholic fatty liver disease (NAFLD).HPN-01 effectively suppress LPS-stimulated secretion of TNF-α, IL-1β, and IL-6 from human PBMCs (pIC50=6.1, 6.4, and 5.7, respectively). HPN-01 also inhibits TNF-α-induced NF-κB nuclear translocation in human lung fibroblast cells (pIC50=5.7). |
分子量 | 401.87 |
分子式 | C19H16ClN3O3S |
CAS No. | 928655-63-4 |
Powder: -20°C for 3 years | In solvent: -80°C for 1 year
对于不同动物的给药剂量换算,您也可以参考 更多...
请在以下方框中输入您的动物实验信息后点击计算,可以得到母液配置方法和体内配方的制备方法: 比如您的给药剂量是10 mg/kg,每只动物体重20 g,给药体积100 μL,一共给药动物10 只,您使用的配方为5% DMSO+30% PEG300+5% Tween 80+60% ddH2O。那么您的工作液浓度为2 mg/mL。
母液配置方法:2 mg 药物溶于 50 μL DMSO (母液浓度为 40 mg/mL), 如您需要配置的浓度超过该产品的溶解度,请先与我们联系。
体内配方的制备方法:取 50 μL DMSO 主液,加入 300 μL PEG300, 混匀澄清,再加 50 μL Tween 80,混匀澄清,再加 600 μL ddH2O, 混匀澄清。
您可能有的问题的答案可以在抑制剂处理说明中找到,包括如何准备库存溶液,如何存储产品,以及基于细胞的分析和动物实验需要特别注意的问题。
HPN-01 928655-63-4 Others HPN01 HPN 01 Inhibitor inhibitor inhibit